Answers are grounded in this paper and cite their sources.
Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2-p53 protein-protein interaction has been pursued as a new cancer therapeutic strategy. In recent years, potent, selective, and efficacious MDM2 inhibitors have been successfully obtained and seven such compounds have been advanced into early phase clinical trials for the treatment of human cancers. Here, we review the design, synthesis, properties, preclinical, and clinical studies of these clinical-stage MDM2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: